Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside.

Yousef Zakharia,Ryan Reis,Rohan Garje,Umang Swami, Janelle M Born,James A. Brown,Kenneth Gerard Nepple,Bashar Abuqayas, Maheen Rajput,Andrew Bellizzi,Jessica C Sieren,Youcef M. Rustum

Journal of Clinical Oncology（2021）

引用 1|浏览5

暂无评分

摘要

322Background: Hypoxia induced factor 1α/2α (HIFs) and vascular endothelial growth factor (VEGF) are overexpressed in ccRCC and associated with increased tumor angiogenesis, vascular instability an...

查看译文

关键词

Tumor Regression

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要